Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO) (MDR-ECMO)

U

University of Padova

Status

Completed

Conditions

Respiratory Distress Syndrome, Adult
Multi-antibiotic Resistance

Study type

Observational

Funder types

Other

Identifiers

NCT06199141
MDR GN bacteria in VV-ECMO

Details and patient eligibility

About

Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a life-support technique used in patients with most severe acute respiratory distress syndrome (ARDS). ARDS is a life-threatening form of respiratory failure associated with a mortality rate of approximately 40-45%.Despite several studies confirming a real benefit of the use of ECMO in patients with ARDS who are unresponsive to conventional management, ECMO is still a complex and costly treatment that can be exposed to potential complications, such as nosocomial infections (NI).

Full description

Noteworthy, the most frequent NIs occurring during VV-ECMO are pneumonia (>40%) and, secondly, blood-stream infections (3-18%). The situation is more challenging for Gram-negative bacilli: more than one-half of the Escherichia coli and more than one-third of the Klebsiella pneumoniae isolates were resistant to at least one antimicrobial group. Of note, an alarming increase in carbapenem resistance has been reported in several species, including K. pneumoniae (7.9% of isolates), P.aeruginosa (16.5% of isolates) and A. baumannii (>30% of isolates). In fact, the isolation of MDROs has been shown to be an independent risk of death and of subsequent infections not only in critically ill patients but also in those patients requiring VV-ECMO (mortality rate between 56-68%). However, data are still conflicting about the exact incidence of multidrug resistant organisms (MDRO) during VV-ECMO and the impact on short- and mid-term outcomes.

Enrollment

279 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ARDS
  • VV-ECMO

Exclusion criteria

  • pregnancy
  • age < 18
  • uncompleted records
  • survival < 24h after ECMO connection

Trial design

279 participants in 1 patient group

VV-ECMO patients
Description:
Patients requiring VV-ECMO for acute respiratory distress syndrome (ARDS)

Trial contacts and locations

1

Loading...

Central trial contact

Annalisa Boscolo, MD; Paolo Navalesi, Prof

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems